Endocrine gland neoplasm

Researchers test a new surgical approach for thyroid cancer that has invaded the windpipe. They replace the affected section with a preserved aortic graft supported by a silicone stent. The goal is to remove all cancer and improve survival. The trial includes patients whose cance…

This study tests whether liver transplantation can extend survival for adults with colorectal cancer that has spread only to the liver and cannot be removed or destroyed by local treatments. About 260 participants aged 18 to 65 will receive a new liver from a deceased or living d…

This trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

Researchers are testing whether a liver-sparing form of chemoembolization, called partial TACE, can boost the anti-tumor effects of the drug lenvatinib in people with liver cancer that cannot be removed by surgery. The trial enrolls about 40 adults with hepatocellular carcinoma w…

This study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …

This phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are studying whether adding local treatments such as ablation, radiotherapy, or transarterial therapy to the drug combination atezolizumab plus bevacizumab helps certain patients with unresectable hepatocellular carcinoma live longer. The study uses medical records an…

Researchers are testing whether a new combination of two antibodies, JS207 and JS007, works better than the standard first-line treatment of toripalimab plus bevacizumab for advanced liver cancer. The trial enrolls about 560 adults with liver cancer that cannot be removed by surg…

Researchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …

Researchers are testing a combination of paclitaxel polymeric micelles and ivonescimab in adults with small cell lung cancer that has returned or stopped responding after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. The phase 2 trial aims to see how many participants'…

This study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…

This phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (…

Researchers are studying whether microwave ablation, helped by a saline injection that separates the liver tumor from the diaphragm, is safe and effective for hepatocellular carcinoma. They compare this approach with surgical resection in patients whose single tumor is 5 cm or sm…

Researchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…

Researchers are testing whether a higher dose of proton beam therapy can normalise hormone levels better than standard radiotherapy in people with functioning pituitary tumours, including acromegaly and Cushing's disease. Participants receive about six weeks of either standard-do…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

Researchers are testing whether an experimental immunotherapy called ZG005, combined with bevacizumab, works better than the standard combination of sintilimab and bevacizumab for people with advanced hepatocellular carcinoma who have not yet received systemic treatment. The tria…

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

Researchers are testing a drug called 3D185 in people with advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, whose tumors have changes in the FGFR2 gene. All participants have already received at least one other systemic cancer treatment that stopped working.…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…

This trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…

This phase III trial compares an experimental combination of two drugs, QLC5508 and QL2107, against the current standard treatment (tislelizumab plus chemotherapy) as a first-line therapy for people with extensive-stage small cell lung cancer. The study enrolls adults who have no…

This phase 2 trial tests whether combining an experimental drug called SHR-7787 with the immunotherapy adebrelimab can help people with limited-stage small cell lung cancer. The study enrolls adults aged 18 to 75 whose cancer has not progressed after standard chemotherapy and rad…

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …

This study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors and control advanced Merkel cell cancer in people whose disease has worsened after standard immunotherapy. About 31 adults with stage III or IV Merkel cell canc…

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…

This study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…

This trial tests a cell therapy called DC-CTL, made from a patient's own immune cells, combined with standard anti-tumor treatment. The goal is to see if this approach is safe and may help control solid tumors such as colorectal, esophageal, lung, liver, and breast cancer. About …

This first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…

This phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…

This trial tests whether giving hydrocortisone during and right after pancreatic surgery can lower the risk of a postoperative pancreatic fistula, a serious leak of digestive fluids. About 20 adults with pancreatic, duodenal, or bile duct cancer will be randomly assigned to recei…

This phase 3 trial tests whether the experimental drug ZL-1310, when combined with an immunotherapy drug, can help people with extensive-stage small cell lung cancer live longer than those receiving standard chemotherapy plus immunotherapy. The study enrolls about 530 adults who …

This Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…

This phase 2 trial tests whether daraxonrasib, an oral drug that targets cancers with a KRAS mutation, can shrink tumors in people with advanced biliary tract cancer that has progressed after first-line treatment. Participants take the drug once daily in 28-day cycles. The main g…

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker …

This trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…

This trial tests whether combining three treatment approaches can reduce the chance of liver cancer returning after surgery. People who had their liver cancer completely removed but showed signs of microvascular invasion, a risk factor for recurrence, will receive chemotherapy di…

This phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…

This early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…

This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…

This study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…

This study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…

This early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…

This trial asks whether monitoring a slow-growing head and neck tumor without immediate treatment can preserve quality of life better than early surgery or radiation. Adults with newly diagnosed carotid or vagal paragangliomas are randomly assigned to either active surveillance o…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…

This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how ma…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This study looks at how well the drug surufatinib works and how safe it is for people with neuroendocrine tumors, a type of cancer that grows from hormone-producing cells. Researchers will follow about 60 patients who receive surufatinib either alone or with other treatments, as …

This phase II trial is testing whether adding tocilizumab, an anti-inflammatory drug, to a standard two-drug immunotherapy regimen can reduce severe immune-related side effects in people with advanced liver cancer. The study enrolls about 51 adults with hepatocellular carcinoma t…

This Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…

This early-stage trial is testing an experimental drug called zanzalintinib in children and teens with solid tumors that have returned or not responded to standard treatment. The main goals are to find the highest safe dose and to see how well the drug is tolerated. Participants …

This trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …

This trial tests whether a wearable device and a personalized prehabilitation program can help adults recover better after surgery for pancreatic cancer or related conditions. Participants will wear a monitor to track vital signs and activity, and follow a program of exercise, nu…

This trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…

This study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …

This trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…

This study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…

This phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…

This study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…

This phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…

This trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…

This trial investigates whether eating purple-fleshed potatoes daily for four weeks can improve blood pressure and other heart health markers in men with prehypertension. Participants will consume either purple or white potato puree in a crossover design, with measurements taken …

This trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…

This trial investigates whether ebastine, a widely used allergy medication, can reduce the risk of liver cancer returning after surgery. The study enrolls people with a specific high-risk tumor feature called tumor budding. All participants will take ebastine daily for a year, an…

This umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …

This early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…

This study looks at whether combining the targeted drug donafenib with an immunotherapy drug and a liver-directed procedure (either chemoembolization or infusion chemotherapy) can help people with unresectable hepatocellular carcinoma — liver cancer that cannot be removed by surg…

This trial is testing whether a combination of two drugs—sacituzumab tirumotecan and envafolimab—can shrink advanced biliary tract cancers (cancers of the bile ducts or gallbladder) that have grown despite initial treatment. The study enrolls up to 28 adults whose tumors carry a …

This trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …

This trial investigates whether adding dapagliflozin—a drug typically used for diabetes—to standard first-line therapy can improve tumor response in people with advanced liver cancer that cannot be surgically removed and who also have metabolic syndrome. About 44 participants wil…

This trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…

This phase 2 trial is testing whether adding zolbetuximab, an antibody that targets a protein called claudin 18.2, to standard chemotherapy can help control advanced or metastatic biliary tract cancers. The study enrolls adults whose tumors overexpress this protein. Participants …

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to t…

This trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…

This phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the dru…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study…

This early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…

This phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …

This phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …

This study looks back at how well a type of targeted radiation therapy (PRRT) works for people with advanced pheochromocytoma and paraganglioma, rare tumors of the adrenal glands. Researchers will analyze data from about 210 patients treated in Italy over 24 years. The goal is to…

This trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intrav…

This clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests a drug called sacituzumab tirumotecan in people with two rare cancers: adenoid cystic carcinoma (a type of salivary gland cancer) and papillary thyroid carcinoma that have returned or spread. About 68 participants will receive the drug through an IV twice a month…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests a procedure that uses a thin needle guided by an endoscope to inject alcohol into a benign adrenal tumor that produces too much aldosterone, a hormone that raises blood pressure. The goal is to destroy the tumor without surgery. The trial enrolls 30 adults with l…

This clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …

This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with advanced biliary tract cancer whose disease has worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to seek out and deliver chemotherapy directly t…

This study tests a combination of two drugs (vebecotototo and putli monoclonal antibodies) in 44 people with advanced bile duct cancer that has a specific marker (EGFR) and has not responded to prior treatment. The goal is to see if the combination can shrink tumors and control t…

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…

This phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …

This study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…

This clinical trial is testing a combination of two experimental drugs, IMM2510 and IMM27M, in people with advanced hepatocellular carcinoma (a type of liver cancer) who have not yet received treatment for their advanced disease. The drugs are designed to help the immune system r…

This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…

This trial tests an experimental drug called CTX-471 in people with advanced neuroendocrine tumors that have a specific marker (NCAM) and have stopped responding to standard treatments. Participants receive the drug by IV every two weeks. The study aims to see if the drug can shr…

This study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then und…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This phase II trial is testing whether a combination of treatments can help people with a type of liver cancer that cannot be removed by surgery. The approach uses local chemotherapy delivered directly to the liver, along with immunotherapy (toripalimab) and a targeted therapy pi…

This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …

This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can …

This study compares two surgical approaches for unilateral thyroid cancer: a newer, scar-free endoscopic technique through the armpit versus standard open neck surgery. Researchers will track complications, recovery time, and patient satisfaction in 400 adults aged 18-70 with ear…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve sur…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…

This study tests whether a common antibiotic for women's UTIs, fosfomycin-trometamol, works well for men with urinary tract infections. Current treatments can have serious side effects and increase antibiotic resistance. The trial will enroll 138 men in primary care and monitor f…

This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct…

This phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…

This trial tests a drug called HRX215 in 80 adults with colorectal cancer that has spread to the liver. Before surgery to remove liver tumors, patients often get a procedure (PVE) that blocks blood flow to the tumor area to encourage the healthy part of the liver to grow. HRX215 …

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to …

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a combination of four drugs (epalrestat, HAIC, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can control the cancer for at …

This study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …

This early study tests if a new, needle-based treatment using brief electric pulses can safely destroy certain pancreatic tumors without surgery. The treatment aims to spare healthy tissue nearby. About 12 adults with specific pancreatic cysts or low-grade tumors will be enrolled…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumor…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests whether removing only the cancerous part of the thyroid and nearby lymph nodes on one side is safe and effective for sporadic medullary thyroid cancer. Currently, all patients get the entire thyroid removed, which requires lifelong hormone pills and carries highe…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This study tests whether a newer, shorter metal stent works better than a standard plastic stent for opening blocked bile ducts in people with pancreatic cancer who need surgery. About 116 adults with operable or locally advanced pancreatic cancer and high bilirubin levels will b…

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…

This study tests whether adding a special thermal therapy (which freezes and heats tumors) to standard targeted therapy and immunotherapy can help people with advanced liver cancer that cannot be removed by surgery. About 166 participants will be randomly assigned to receive eith…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new drug called ZG006 against standard chemotherapy for people with advanced neuroendocrine carcinoma, a type of cancer. About 240 adults who have already had other treatments will be randomly assigned to receive either ZG006 or a chemotherapy chosen by their d…

This study tests if adding a targeted drug (becotatug vedotin) to standard chemotherapy and immunotherapy helps shrink tumors better than standard treatment alone in people with advanced bile duct cancer that has a specific gene change (EGFR mutation). About 164 adults with this …

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectabl…

This trial is testing a new way to treat intermediate and advanced liver cancer. It combines two liver-directed procedures (HAIC and TACE) with two drugs (apatinib and camrelizumab) to see if this approach works better than other combinations. The study will involve 315 adults wi…

This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measur…

This phase 3 trial tests whether adding chemotherapy after surgery can prevent aggressive pancreatic neuroendocrine tumors from coming back. About 300 patients will either receive active surveillance alone or 6 cycles of capecitabine-temozolomide pills plus surveillance. The stud…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 people with advanced liver cancer that has stopped responding to standard treatments. The drug is designed to boost the immune system by blocking two cancer defenses at once. The main goal is to check safety a…

This study looks at people with papillary thyroid cancer tumors 2 to 4 cm who are having thyroid surgery. Half will also have nearby neck lymph nodes removed, and half will not. The goal is to see if removing these nodes lowers the chance of cancer coming back or persisting, and …

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests whether a combination of two drugs—adebrelimab (given by IV) and S-1 (taken as pills)—can help prevent bile duct cancer from returning after surgery. About 40 adults who had their cancer fully removed will receive the treatment for about 4 months and be monitored…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver c…

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.

This early-stage trial tests a new drug called BL0020 combined with the immunotherapy Toripalimab in 33 people whose extensive-stage small cell lung cancer has returned after initial treatment. The main goal is to check safety and find the right dose, while also seeing if the com…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy drugs) plus targeted chemotherapy delivered directly to the liver (TACE-HAIC) as a first treatment for people with unresectable hepatocellular carcinoma. About 38 participants will rec…

This phase 2 trial tests a combination of nab-paclitaxel (a chemotherapy drug) and local radiation therapy for people with extensive-stage small-cell lung cancer whose disease has worsened after initial treatment. The study aims to see if this combo can improve progression-free s…

This phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…

This study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…

This study looks at whether starting denosumab early, along with a standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults with liver cancer and bone metastases will be r…

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be r…

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and t…

This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This study tests whether giving a mix of chemotherapy, immunotherapy, and targeted therapy before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 participants will either receive the combination treatment followed by surgery, o…

This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good perfor…

This phase II trial tests an experimental drug called SHR-A1904 in 23 people with advanced neuroendocrine carcinoma whose cancer has worsened after standard chemotherapy. The study measures how many patients have their tumors shrink or disappear, how long they live without the ca…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combina…

This study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…

This phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…

This study tests two drugs together—pucotenlimab (which helps the immune system fight cancer) and becotatugvedotin (which targets and kills cancer cells)—in people with advanced bile duct cancer that has not responded to prior treatment. The main goal is to see how many patients'…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines a type of internal radiation (Y-90) with two immunotherapy drugs (durvalumab and tremelimumab) and a targeted therapy pill (zanzalintinib). The goal is…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…

This Phase 2 trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancers live longer without their cancer growing. About 126 adults who have not had prior treatment for advanc…

This study tests a new, affordable type of radioactive microsphere for treating liver cancer that cannot be removed by surgery. The microspheres are delivered directly to the tumor through a blood vessel, delivering radiation to kill cancer cells. The trial will enroll 18 adults …

This phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that can…

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…

This study will enroll 40 people with high-risk differentiated thyroid cancer who need radioactive iodine therapy. After stopping their own thyroid hormones, participants will receive either standard levothyroxine alone or levothyroxine plus liothyronine. The goal is to see which…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 people with extensive-stage small cell lung cancer whose disease got worse after initial chemotherapy plus immunotherapy. The goal is to see if the combo can shrink tumors or slow cancer gro…

This study tests whether injecting a blue dye called mitoxantrone hydrochloride into the thyroid during robotic surgery helps surgeons see and remove cancer-affected lymph nodes while avoiding the parathyroid glands. 114 people with papillary thyroid cancer will be randomly assig…

This phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This study tests whether blocking the artery that feeds a bile duct tumor before surgery can make it possible to remove the cancer safely. It includes 33 adults with advanced bile duct cancer that currently cannot be operated on. The main goal is to see how many patients are aliv…

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. Th…

This phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…

This study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly a…

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This phase 3 trial tests whether combining desiccated thyroid extract (DTE) with standard levothyroxine can help intermediate-to-high risk thyroid cancer patients reach their TSH suppression targets faster and more safely after surgery. Many patients on levothyroxine alone strugg…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to se…

This study tests a procedure called irreversible electroporation (IRE), also known as Nanoknife, to treat liver tumors that have spread from colorectal cancer. IRE uses short electrical pulses to destroy cancer cells while sparing nearby blood vessels and bile ducts. The trial wi…

This study looks at patients with advanced liver cancer that cannot be removed by surgery at first. They receive a combination of treatments—chemotherapy directly into the liver, anti-angiogenic drugs, and immunotherapy—to shrink the tumor. If the tumor shrinks enough to become r…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers tha…

This study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangi…

Researchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…

This trial is testing whether a new type of PET/CT scan, using a tracer that targets a protein called DLL3 found on many neuroendocrine tumor cells, can detect cancer spread more accurately than standard scans. About 200 adults with metastatic neuroendocrine tumors will receive b…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This study tests whether a new eye-tracking device called SONDA can accurately measure visual field loss in people with pituitary tumors. Standard visual field tests require patients to press a button when they see lights, which can be tiring and unreliable. The SONDA test instea…

This study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…

This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.

This study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…

This study looks at whether a genetic test called Thyroid GuidePx® can help doctors and patients with papillary thyroid cancer make better treatment choices. About 85 adults with early-stage thyroid cancer will take the test before surgery. Researchers will see if the test result…

This study compares two contrast-enhanced ultrasound scoring systems (LI-RADS and ESCULAP) to see which one better detects recurrent liver cancer in 105 patients who have had surgery for hepatocellular carcinoma. The goal is to improve diagnostic accuracy for new liver lesions. P…

This study tests whether a special ultrasound technique, called contrast-enhanced subharmonic ultrasound, can predict if chemotherapy is working for stomach cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see tumor shrinkage. Thi…

This study will test whether using a contrast agent called Sonazoid during ultrasound can find early-stage liver cancer better than standard ultrasound alone. About 556 adults with liver cirrhosis will be scanned every 4 to 6 months. The goal is to see if this method catches more…

This study tests a special ultrasound technique called contrast-enhanced subharmonic ultrasound to see if it can predict whether chemotherapy is working for colorectal cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see if tumors…

This study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests whether a special PET scan (18FET) can find small pituitary tumors that standard MRI scans miss. About 30 adults with suspected hormone-secreting pituitary tumors will receive the scan. If it works, it could help doctors decide on surgery or radiation without nee…

This study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…

This study tests a new light-based monitor (NIRS) that checks oxygen levels in the abdomen of preterm infants. Researchers want to see if it works reliably and safely on 50 babies born before 35 weeks. If it does, it could help doctors quickly detect life-threatening gut problems…

This study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver disease…

This trial tests whether stimulating specific acupoints—using herbal patches or mild electrical pulses—can help the bowels recover more quickly after liver cancer surgery. Patients scheduled for partial liver removal will be randomly assigned to one of four groups: herbal patches…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This phase II trial tests whether a low dose of the cancer drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will take either erlotinib or a placebo daily for a set period. The study will measure changes in a blood protei…

This study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check…

This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…

Researchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…

Researchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…

Cancer near the liver's bile duct junction can block bile flow, causing jaundice and infection. Doctors usually drain the bile with a plastic stent placed through an endoscope. This trial randomly assigns about 70 adults with inoperable high-grade hilar biliary obstruction to one…

This pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…

This study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…

This study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meet…

This study tests whether scheduled meditation using the Headspace app can improve recovery after pancreatectomy (surgery to remove part of the pancreas). Seventy patients will be asked to meditate regularly before and after surgery, and researchers will track pain, anxiety, sleep…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

Shortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

Many people with small thyroid cancers can choose between a less extensive surgery (lobectomy) or a more extensive one (total thyroidectomy), yet some pick the riskier option without clear reason. This study tests whether an electronic decision navigation tool — one that highligh…

This pilot trial tests whether adding emotional support to a cancer information website helps young adults (ages 20-39) with thyroid, melanoma, or testicular cancer feel less worried and distressed. 142 participants will either get general cancer info or the same info plus person…

This study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This early study tests an augmented reality (AR) system that overlays a tumor's image onto the liver during keyhole surgery. Six adults scheduled for liver tumor removal will participate. The goal is to see if the AR guidance helps surgeons remove tumors more completely and safel…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests whether giving lidocaine through a vein during and after liver surgery can reduce side effects like nausea, vomiting, and breathing problems caused by opioid painkillers. About 312 adults having planned open liver surgery will be randomly assigned to receive eith…

This study tests whether offering free rideshares, hotel stays, and meal delivery helps low-income liver cancer patients start treatment sooner. About 75 uninsured or underinsured adults with liver cancer will be randomly assigned to receive these social supports plus usual patie…

This Phase 2 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced liver cancer who are losing weight and appetite. About 88 patients will receive either the drug or a placebo for 12 weeks while also getting standard cancer therapy. The…

This study is testing a program called Care and Connect, where trained volunteers provide support and information to people with lung cancer. The goal is to see if this program helps reduce distress and makes it easier for patients to get the care they need. About 50 adults with …

Low-risk thyroid cancer grows very slowly and has a 99% survival rate, but choosing among three treatment options can be stressful. This study gives patients a decision aid pamphlet right after diagnosis, before they see a surgeon. The pamphlet explains the options and lists ques…

This study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…

This trial tests a new way to place plastic stents in the bile duct for people with jaundice caused by cancer near the liver. The standard method places the stent across the bile duct opening, while the new method places it above the opening without cutting the muscle. The study …

This study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…

Researchers at Sohag University Hospitals are reviewing the medical records of 30 people treated for papillary thyroid cancer, the most common type of thyroid cancer. The study examines how far tumors extended beyond the thyroid gland and which complications appeared soon after s…

After thyroid surgery for differentiated thyroid cancer, patients often need to take thyroid hormone at doses that keep TSH in a specific target range. Researchers at West China Hospital are testing whether adding a short educational video to standard instructions helps patients …

Researchers at Karolinska University Hospital are following 900 people diagnosed with intrahepatic or perihilar cholangiocarcinoma, two types of bile duct cancer. The study tracks how tumors respond to treatment, how patients feel and function, and changes in biomarkers over time…

Researchers at Yale University are using PET brain scans with a radioactive tracer called [11C]OMAR to measure CB1 receptor levels in people with opioid use disorder who are stabilized on buprenorphine, compared to healthy controls. The study aims to see if CB1 receptor availabil…

Researchers at a Moscow medical center are studying the quality and outcomes of thyroid surgery using real-world clinical data. The study follows patients who had thyroid operations for benign or malignant disease, tracking complications, cancer results, and long-term outcomes. B…

This observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This observational study follows 400 people with intermediate to advanced or unresectable hepatocellular carcinoma (the most common type of liver cancer) who are receiving systemic therapies such as atezolizumab plus bevacizumab or nivolumab plus ipilimumab, sometimes combined wi…

Researchers are collecting blood and tumor tissue samples from 30 adults with relapsed small-cell lung cancer who are receiving a standard DLL3 T cell engager therapy. The goal is to track changes in tumor markers over time and see if those changes relate to how well the treatmen…

This study aims to build and test a model that predicts the risk of developing liver cancer (hepatocellular carcinoma) in people with hepatitis B-related liver fibrosis or cirrhosis. Researchers will analyze data from 2000 patients, including their medical history, blood sugar ma…

Researchers at Odense University Hospital are testing whether monitoring brain signals during tumor surgery can help preserve functions like movement, speech, and vision. The project includes a randomized trial comparing surgery with and without motor signal monitoring, plus obse…

This study looks at a surgical technique called the extended endoscopic endonasal approach (EEEA), which removes skull base lesions through the nose. The goal is to see how completely the tumor can be removed and how safe the procedure is. Adults with certain skull base tumors, s…

This study looks at how patients with radioiodine-refractory differentiated thyroid cancer are treated in the real world after first-line therapy stops working. It will compare two approaches: a targeted combination (dabrafenib plus trametinib) guided by a specific gene mutation,…

This study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …

This study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…

This study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…

This study investigates whether substances in the blood can predict how patients with advanced liver cancer respond to a combination of atezolizumab and bevacizumab. Researchers will analyze leftover blood samples from routine tests in 100 patients to look for patterns linked to …

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study investigates whether a specialized MRI scan called three-dimensional magnetic resonance elastography (3D-MRE) can predict how well patients with initially unresectable liver cancer will respond to conversion therapy. The scan measures the stiffness and other physical p…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers w…

This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces seri…

This study explores whether a special 3D MRI scan, called magnetic resonance elastography, can measure liver stiffness and elasticity before surgery to predict the risk of liver failure afterward. Researchers will enroll 150 adults with liver cancer or liver metastases who are sc…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study is testing whether a blood test can locate where colorectal cancer has returned or spread after surgery. Researchers are analyzing genetic markers in the blood to build a model that predicts whether a recurrence is local or distant. The goal is to improve early detecti…

This study explores whether a special imaging technique called parenchymal blood volume (PBV) imaging can detect changes in blood flow within liver tumors after giving a drug called nitroglycerin. The drug is commonly used for heart conditions but may temporarily increase blood f…

This study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…

This study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…

This observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…

This study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…

This study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…

This study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…

This study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study tests a computer vision model called PTAIR that helps surgeons identify parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. About 100 adults with thyroid disease will take part. The model's ability to spot these structures will be compa…

This study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…

This study looks at whether giving patients clear, standardized instructions before and after pituitary surgery can improve their recovery. Researchers will compare hospital stay length, complication rates, and unplanned readmissions in 102 adults having elective surgery. The goa…

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This study tests whether an artificial intelligence (AI) model can predict how well liver cancer patients will respond to a combination of treatments, including a procedure called TACE, immunotherapy, and targeted therapy. Researchers will analyze medical images and other data fr…

This large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the be…

This study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This early-phase trial tests an artificial intelligence system that watches live video from pituitary tumor surgeries performed through the nose. The AI identifies anatomy, instruments, and surgical steps, displaying its analysis on tablets for the surgical team (not the lead sur…

This observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, …

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study looks at whether non-diabetic patients who have pancreas surgery can safely avoid routine insulin afterward. About 290 adults will be randomly assigned to receive either standard insulin or no insulin after surgery. The goal is to see if skipping insulin keeps blood su…

This study aims to improve how doctors predict and monitor thyroid cancer by combining genetic testing of tumors with protein analysis from urine samples. Researchers will follow 100 newly diagnosed thyroid cancer patients to see if these markers can detect early signs of recurre…

This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …

This study will enroll 200 patients scheduled for surgery to remove rare adrenal tumors called pheochromocytomas or paragangliomas (PPGL). Before surgery, researchers will use a model to predict the risk of severe blood pressure swings during the operation. During surgery, a real…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …

This study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…

This study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…

This study will create a registry of about 120 patients in Poland who have carcinoid heart disease, a rare complication of neuroendocrine tumors that damages heart valves. Researchers will collect medical records, echocardiograms, and lab results to better understand who develops…

This study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…

This study aims to create a 3D model of the bile ducts using MRI and CT scans, along with an AI tool to help doctors guide a camera during a procedure called ERCP. The goal is to improve safety and accuracy. The study will use existing medical images from 100 adult patients who h…

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …

This trial compares two techniques used when standard bile duct access fails during ERCP: pre-cut sphincterotomy and the double guidewire technique. Researchers will enroll 840 adults with difficult bile duct cannulation to see which method is safer and more successful. The goal …

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look…

This study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-w…

This study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommenda…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study will enroll 100 adults with neuroendocrine tumors who are starting oral anti-cancer drugs like everolimus or sunitinib. Researchers want to see if a therapeutic education program—including questionnaires and nurse consultations—helps patients handle side effects and ma…

This observational study will measure Omega-6 fatty acid levels in the blood of 100 adults — half with liver cancer and half without — to see if there is a connection. No drugs or treatments are given. The goal is to understand if these fats are linked to the presence or severity…

This study follows 1,630 people with a small, low-risk thyroid cancer to compare three management options: surgery, heat ablation (a minimally invasive procedure), or active surveillance (monitoring without immediate treatment). The goal is to see which approach offers the best s…

This study focuses on a rare and aggressive type of cervical cancer called large cell neuroendocrine carcinoma (LCNEC). Researchers will look back at medical records and follow 200 patients over time to understand the disease's behavior and what factors affect survival. The goal …

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This observational study will follow 522 adults across Europe who are having surgery to remove an adrenal gland tumor. The goal is to track heart-related complications within 30 days after surgery and understand how different hospitals prepare patients beforehand. By collecting r…

This study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…